RaphaelLandovitzMDMSc
Infectious Disease • Los Angeles, CAHIV/AIDS Medicine
UCLA Center for Clinical AIDS Research & Education
Dr. Landovitz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1399 S. Roxbury Dr, Suite 100
Los Angeles, CA 90035Phone+1 310-557-2273Fax+1 310-557-3450
Summary
- Dr. Raphael Landovitz is an infectious disease specialist in Los Angeles, CA and is affiliated with multiple hospitals in the area, including Ronald Reagan UCLA Medical Center and UCLA Medical Center-Santa Monica. He received his medical degree from Harvard Medical School and has been in practice 20 years. He also speaks multiple languages, including Spanish and Vietnamese. He specializes in hiv/aids medicine and is experienced in hiv/aids and sexually transmitted infections.
Education & Training
Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1999 - 2001
Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 1999- Brigham and Women's HospitalInternship, Internal Medicine, 1996 - 1997
Harvard Medical SchoolClass of 1996
Certifications & Licensure
CA State Medical License 2006 - 2026
VT State Medical License 2016 - 2026
MA State Medical License 1998 - 2007- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Comparative Study of Three NNRTI-Sparing HAART Regimens Start of enrollment: 2009 May 01
- Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV Start of enrollment: 2010 Mar 01
- A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services Start of enrollment: 2013 May 01
- Join now to see all
Publications & Presentations
PubMed
- Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VR...Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, Yunda Huang, Carmen A Paez
The Lancet. HIV. 2024-12-09 - Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083.Meredith E Clement, Brett Hanscom, Daniel Haines, Jose A Bazan, Nuntisa Chotirosniramit
Clinical Infectious Diseases. 2024-11-23 - 3 citationsType 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1...Raphael J Landovitz, Li Tao, Juan Yang, Melanie de Boer, Christoph Carter
Clinical Infectious Diseases. 2024-11-22
Journal Articles
- Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-Uninfected Individuals: HPTN 077, a Phase 2a Randomized Controlled TrialSusan H Eshleman, Joseph J Eron, Raphael J Landovitz, Myron S Cohen, Jeremy Sugarman, Mark A Marzinke, Craig W Hendrix, PLoS One
- Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large HIV Treatment-Naive Clinical TrialRaphael J Landovitz, Judith S Currier, Clinical Infectious Diseases
Press Mentions
UCLA’s HIV Prevention and Treatment Center Receives $7.5 Million Grant from NIHMarch 17th, 2022- Breakthrough HIV Reported in Injectable PrEP Trial; Experts Say Drug Still Very EffectiveFebruary 16th, 2022
- Cabotegravir Bests TDF-FTC for HIV Prevention in Those at RiskAugust 13th, 2021
- Join now to see all
Other Languages
- Spanish, Vietnamese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
